# REVELIO Pilot Study Tests In-Vehicle Detection of Cannabis-Impaired Driving > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-revelio-pilot-study-tests-in-vehicl-2026-10-02/ > **Published:** 2026-10-02T13:06:57-04:00 | **Last Modified / Clinically Audited:** 2026-10-02T13:06:57-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recr... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving.. Clinical Insight | CED Clinic REVELIO is important because it moves the cannabis-driving conversation beyond blood THC alone. The protocol enrolls 45 healthy recreational cannabis users, randomizes them to controlled inhaled cannabis or no cannabis, and measures driving behavior repeatedly on a secured test track for about six hours. The intervention targets 0.67 mg THC per kg body weight, a substantial inhaled dose. Its most clinically relevant feature is triangulation: capillary blood, breath, oral fluid, performance assessments, vehicle CAN data, driver camera data, and wearable physiology. For clinicians, this design underscores that impairment is functional, time-dependent, and not reducible to a single laboratory number. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: REVELIO Pilot Study Tests In-Vehicle Detection of . Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42821661/) Table of Contents - [REVELIO Pilot Study Tests In-Vehicle Detection of Cannabis-Impaired Driving](#REVELIO_Pilot_Study_Tests_In-Vehicle_Detection_of_Cannabis-Impaired_Driving)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # REVELIO Pilot Study Tests In-Vehicle Detection of Cannabis-Impaired Driving A new German test-track protocol will study whether vehicle data, driver monitoring, wearables, and THC biomarkers can help identify cannabis-related driving impairment in real time. What This Study Teaches Us This protocol describes a randomized, controlled, open-label, single-centre pilot study enrolling 45 healthy recreational cannabis users, with an inhaled cannabis target dose of 0.67 mg THC per kg in the intervention arm and no cannabis in the reference arm. Planned endpoints include three post-baseline 50-minute closed-track driving sessions up to about six hours, biological THC measures, pre-driving assessments, CAN vehicle data, driver camera data, wearable physiology, and machine-learning classification of sober versus cannabis-influenced states. Why This Matters The study matters because current clinical and legal conversations often overemphasize THC concentration despite weak alignment between blood levels and actual driving function. If feasible, multimodal impairment detection could improve harm reduction counseling, post-dose driving advice, and future safety systems, while also exposing the limits of biomarker-only policies. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourcePloS onePublication Date2026Evidence LevelJournal Article, Clinical Trial ProtocolFocus AreaREVELIO Pilot Study Tests In-Vehicle Detection of Cannabis-ILead AuthorsRobin Deuber, Michal Bechny, Christoph Heck, Joel Brügger et al.DOI10.1371/journal.pone.0349328PMIDPMID: 42821661 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Headline vs. Reality Truth Meter: Cars may soon be able to detect stoned drivers in real time. **Primary Journal Data:** The paper is a protocol, not a completed validation study. It plans to enroll 45 healthy recreational cannabis users, compare a cannabis intervention group with a no-cannabis reference group, collect multimodal vehicle, driver, wearable, and THC biomarker data, and develop machine-learning models under closed-track conditions. **Dr. Caplan’s Clinical Verdict:** Promising concept, but not ready for roadside enforcement, clinical clearance decisions, or consumer vehicle deployment. The study may generate reference data and feasibility metrics, but it has not yet proven accuracy, generalizability, legal validity, or patient-level safety thresholds. Primary Analysis | Protocol for the REVELIO test-track pilo **Study Overview:** Driving under the influence of cannabis is associated with impaired cognitive and psychomotor performance and an increased risk of traffic accidents. Reliable real-time in-vehicle systems for detecting cannabis-related driving impairment are currently lacking; but hold great potential for improving road safety. This protocol describes the REVELIO test-track pilot study: a randomised, controlled, open-label, interventional, single-centre trial. The study assesses the feasibility and methodological requirements for developing and evaluating a multimodal in-vehicle detection approach using vehicle and driver state data. A total of 45 healthy recreational cannabis users will be enrolled and randomly allocated to an intervention or a reference control group. During the main study day, all participants will undergo biological sampling for tetrahydrocannabinol (THC) and related metabolites, as well as pre-driving assessments, followed by a sober baseline driving session on a closed test track using a dual-pedal vehicle with a certified driving instructor onboard. Participants in the intervention group will then receive a single controlled inhalative cannabis dose (target 0.67 mg THC per kg body weight), while the reference group will receive no cannabis. All participants will subsequently complete three additional standardized 50-minute driving sessions at predefined time points up to approximately six hours after administration, following identical schedules to enable within- and between-group comparisons. Between driving sessions, structured breaks will include recovery periods, repeated biological sampling, and traffic-medical, traffic-psychological, and pre-driving performance assessments, to characterise the temporal dynamics of cannabis-related impairment. Multimodal data will be collected, including vehicle controller area network (CAN) data, driver monitoring camera (DMC) data, physiological signals using wearables, and biological samples (capillary blood, breath, oral fluid. Machine-learning-based models will be developed and evaluated to distinguish sober from cannabis-influenced driving states under controlled conditions. Secondary analyses will examine changes in driving performance over time and associations between functional measures and biological THC concentrations. As an exploratory pilot study conducted on a secured test track, the protocol aims to generate standardized reference data and quantitative performance metrics to inform both feasibility and system design considerations. The study is registered at ClinicalTrials.gov (NCT07401628). **Primary Source & Scope:** Published in *PloS one* (2026) conducted by Robin Deuber, Michal Bechny, Christoph Heck, Joel Brügger et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42821661/) | **Primary Record:** DOI: 10.1371/journal.pone.0349328 | PMID: 42821661 How Strong Is This Evidence? The design is stronger than an observational survey because it uses random allocation, standardized driving sessions, a controlled inhaled THC dose, repeated biological sampling, and a secured test-track environment. The sample size of 45 is appropriate for feasibility and model-development exploration, but it is too small for definitive clinical validation or policy thresholds. Statistical rigor will depend heavily on prespecified machine-learning validation, avoidance of overfitting, and transparent reporting of classification performance. Where This Paper Deserves Skepticism The study is open-label, so expectancy effects may influence subjective effort, anxiety, or driving behavior after cannabis administration. It enrolls healthy recreational users at a single centre, which limits applicability to medical patients, older adults, novice users, people using sedating co-medications, and real traffic conditions. Closed-track driving improves safety and standardization, but may underrepresent fatigue, distraction, weather, social stress, and complex roadway decision-making. What This Paper Does Not Show This protocol does not prove that an in-vehicle system can accurately identify cannabis impairment in the general driving population. It also does not establish a legal THC limit, a universal waiting period after cannabis use, or clinical permission to drive after any specific product or dose. How This Fits With the Broader Clinical Conversation Clinical research into Protocol for the REVELIO test-track pilot study: A is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away This is a thoughtful feasibility protocol, not proof of a deployable cannabis impairment detector. Patients should still be counseled that inhaled THC can impair driving for several hours, and that feeling normal is not a reliable safety test. Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Protocol for the REVELIO test-track pilot stu requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Read this as a protocol, not an outcomes study. No diagnostic performance data have been reported yet. **Critical Rule**Separate functional impairment from THC concentration. The study is designed because biomarkers alone may not capture driving safety. **Critical Rule**Watch future reporting for validation methods, false-positive and false-negative rates, subgroup performance, and real-world generalizability. Key Evaluation Question Will the multimodal model accurately distinguish sober from cannabis-influenced driving without overfitting a small, controlled test-track sample? The Patient Question Given the cannabis product, dose, route, tolerance, other medicines, and medical condition, how long should driving be avoided after use? The Bottom Line REVELIO is a well-conceived pilot protocol that may improve cannabis impairment science, but it does not yet prove an in-vehicle detector is accurate, fair, or ready for clinical or legal use. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis REVELIO is a randomized, controlled, open-label pilot protocol, not a completed clinical results paper. It will enroll 45 healthy recreational cannabis users and compare a controlled inhaled THC condition with a no-cannabis reference condition on a secured test track. The evidence contribution is methodological: repeated 50-minute driving sessions, biological sampling, performance testing, vehicle CAN data, driver camera data, and wearable physiology. The study may clarify which data streams are feasible and informative, but accuracy is not yet established. Lens takeawayThis protocol builds the testing platform, but does not validate the detector yet. #### Patient Communication Patients often ask whether a THC blood level, subjective sobriety, or time since use can determine driving safety. REVELIO highlights why the answer is complicated: impairment changes over time and may appear in attention, lane control, reaction time, and decision-making. Clinicians can use this study to explain that driving advice should consider product type, dose, route, tolerance, sleep, alcohol, other sedatives, and medical conditions. A future device may help, but current counseling must remain conservative. Lens takeawayDriving safety after THC should be discussed as functional impairment, not just intoxication. #### Dosing & Formulations The protocol uses a single controlled inhalative cannabis dose targeting 0.67 mg THC per kg body weight. For a 70 kg participant, that target equals about 47 mg THC administered under controlled study conditions, not a casual or universal clinical dose. Inhaled THC produces rapid onset and changing blood concentrations, which makes timing essential. The study’s repeated sessions up to roughly six hours may help describe how impairment evolves after a defined inhaled exposure. Individualized dose titration, documented cannabinoid ratios, and monitored therapeutic responses remain essential for maximizing clinical benefit while minimizing adverse side effects. Lens takeawayDose, route, and timing strongly shape driving risk after THC exposure. #### Safety & Side Effect Profile The study addresses a genuine safety problem: cannabis can impair psychomotor performance, divided attention, tracking, and reaction time. Using a secured test track and a dual-pedal vehicle with a certified instructor reduces danger during the experiment. However, test-track safety does not equal public-road safety. Real roads add unpredictable drivers, pedestrians, weather, fatigue, navigation demands, emotional stress, and distractions that may magnify cannabis-related impairment. Ongoing post-market surveillance, contaminant screening, and standardized adverse-event reporting remain critical safeguards for patient health. Lens takeawayControlled tracks protect participants, but real driving remains more chaotic and risky. #### Regulatory & Policy Dynamics Regulators struggle with cannabis because THC concentrations do not map neatly onto impairment. Some frequent users may have measurable THC after functional recovery, while some infrequent users may be impaired at lower concentrations. REVELIO may help policy discussions by testing functional detection rather than relying only on toxicology. Still, enforcement tools require external validation, fairness testing, privacy safeguards, and clear standards before deployment. Consistent administrative oversight and clear statutory definitions ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayFunctional impairment tools may improve policy, but only after rigorous validation. #### Mechanisms & Physiology THC affects cannabinoid receptors involved in attention, motor coordination, perception of time, risk assessment, and sensorimotor integration. Driving demands all of these functions simultaneously, which is why mild subjective intoxication can still matter. The study’s multimodal design recognizes that physiology and performance may diverge. Blood, breath, and oral fluid THC may not perfectly match steering variability, braking behavior, gaze patterns, heart rate, or task performance. Investigating receptor affinities, pharmacokinetic pathways, and cellular interactions clarifies the biological mechanisms underlying observed clinical outcomes. Lens takeawayCannabis impairment is a brain and behavior state, not only a concentration. #### Research Limitations The protocol is open-label and single-centre, with only 45 healthy recreational users. That is reasonable for a pilot, but too limited for broad clinical, commercial, or legal conclusions. Participants know whether they used cannabis, and the reference group receives no placebo cannabis. Expectancy, motivation, tolerance, and familiarity with cannabis may influence performance and model training. Readers should carefully evaluate cohort composition, potential confounding variables, and study duration before generalizing preliminary findings across broader clinical populations. Lens takeawayPilot design can reveal feasibility, but cannot settle real-world accuracy. #### Future Outlook If the pilot succeeds, the next step should be larger blinded studies across different THC doses, CBD ratios, routes of administration, age groups, tolerance patterns, and medical conditions. External validation is essential. Future research should report sensitivity, specificity, false-positive rates, false-negative rates, calibration, fairness across subgroups, and performance in more realistic driving conditions before any clinical or policy use. Future prospective investigations with standardized formulations and long-term follow-up will provide critical clarity as clinical evidence matures. Lens takeawayThe future value depends on transparent validation, not technological enthusiasm alone. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=REVELIO+Pilot+Study+Tests+In-Vehicle+Detection+of+Cannabis-Impaired+Driving&url=https%3A%2F%2Fcedclinic.com%2Fced-revelio-pilot-study-tests-in-vehicl-2026-10-02%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-revelio-pilot-study-tests-in-vehicl-2026-10-02%2F) [BlueSky](https://bsky.app/intent/compose?text=REVELIO+Pilot+Study+Tests+In-Vehicle+Detection+of+Cannabis-Impaired+Driving%20https%3A%2F%2Fcedclinic.com%2Fced-revelio-pilot-study-tests-in-vehicl-2026-10-02%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving.](https://pubmed.ncbi.nlm.nih.gov/42821661/) Related Reading at CED ClinicContinue exploring the evidence[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications. [More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)[Prenatal Cannabis Exposure and Neurodevelopment: What the New Systematic Review Actually Shows](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) More on this topic: Systematic review analyzing cognitive, behavioral, and developmental trajectories following gestational cannabinoid exposure. [More on this topic: Fetal neurodevelopment](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) ## Frequently Asked Questions Does this study prove that cars can detect cannabis-impaired driving? No. This is a study protocol, meaning it describes the planned trial. It has not yet reported accuracy, sensitivity, specificity, false positives, or false negatives for any in-vehicle detection system. How many people will be studied? The protocol plans to enroll 45 healthy recreational cannabis users. That size is suitable for a pilot feasibility study, but not for definitive clinical or regulatory validation. What cannabis dose will the intervention group receive? Participants in the intervention arm will receive a controlled inhaled cannabis dose targeting 0.67 mg THC per kg body weight. For a 70 kg adult, that target is approximately 47 mg THC under study conditions. Will the control group receive placebo cannabis? No. The summary describes a reference control group that receives no cannabis. That helps comparison but does not fully control for expectancy effects. What will researchers measure during driving? They plan to collect vehicle CAN data, driver monitoring camera data, wearable physiological signals, biological THC samples, traffic-medical assessments, traffic-psychological assessments, and pre-driving performance measures. Why not just use a blood THC level to decide impairment? Blood THC can be informative, but it does not reliably capture functional impairment for every person. Tolerance, timing, route of use, metabolism, and co-exposures can make THC concentration and driving performance diverge. How long after cannabis will participants be tested? After a sober baseline drive, participants complete three additional standardized 50-minute driving sessions at predefined times up to approximately six hours after cannabis administration or the corresponding control period. Is this study performed on public roads? No. It is conducted on a secured test track using a dual-pedal vehicle with a certified driving instructor onboard. That improves safety and standardization. Can [medical cannabis](https://cedclinic.com/cbd-gummies-clinical-insights-review/) patients use this study to know when they may drive? Not directly. The participants are healthy recreational users, and the study has not reported results. Medical patients should follow clinician guidance, product labeling, local law, and conservative safety practices. What is the most practical clinical message right now? THC can impair driving for several hours, especially after inhaled high-THC exposure. Patients should avoid driving after use, particularly when starting cannabis, increasing dose, combining sedatives, or feeling even mildly altered. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).